Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

2024-04-04

临床2期临床结果

ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE)HAE) attacks, today announced the acceptance of two abstracts for presentation at the Consortium of Independent Immunology Clinics (CIIC) Spring 2024 Conference, to be held from April 12-13, 2024, in Arlington, TX. Presentation details: Title: Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients with Hereditary Angioedema Attacks Format: Digital Abstract Display Board Date, time: Saturday, April 13, 11:00-11:20 a.m. CDT (12:00-12:20 p.m. EDT) Title: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial Presenter: John Anderson, M.D. Format: E-Poster Presentation Date, time: Saturday, April 13, 11:20 a.m.-12:00 p.m. CDT (12:20-1:00 p.m. EDT) The posters and associated presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentation sessions at: . About Pharvaris Building on its deep-seated roots in HAE, Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE HAE efficacious, safe, and easy-to-administer alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit . Contact Maggie Beller Executive Director, Head of External and Internal Communications maggie.beller@pharvaris.com

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构